Skip to main content

HLRCC Foundation

Contact & Join

A 95% Response Rate in a Small Trial: Tislelizumab Plus Lenvatinib for FH-Deficient Kidney Cancer

A phase 2 clinical trial published in Nature Communications in September 2026 tested a first-line combination of two drugs — tislelizumab and lenvatinib — in people with advanced fumarate hydratase–deficient kidney cancer (FH-RCC). The results are encouraging. They are also early: the study was small, done at a single hospital, and had no comparison group. Here’s what the paper found, and what it does not change.

A quick refresher

Hereditary leiomyomatosis and renal cell cancer (HLRCC) is caused by a harmful (pathogenic) variant in the FH gene, which makes an enzyme called fumarate hydratase. People with HLRCC can develop benign smooth-muscle growths in the skin and uterus (leiomyomas, including fibroids), and they have a higher risk of a type of kidney cancer. A 2014 expert consensus estimated kidney cancer risk at approximately 15 in 100 (about 15%), which means most people with HLRCC do not get kidney cancer. Learn more in GeneReviews and our HLRCC Handbook.

Not every FH-deficient kidney tumor is inherited. The same enzyme can be lost only in the tumor (somatic changes). GeneReviews notes that staining tests on tumor tissue cannot tell those two situations apart. In this trial, 15 of the 20 patients had a germline (inherited) FH variant, and 5 had somatic FH changes only.

What the researchers tested

Tislelizumab is an immunotherapy drug that blocks PD-1, a “brake” some immune cells use. Lenvatinib is a daily oral targeted therapy in the tyrosine kinase inhibitor (TKI) family. Combinations of this type are already used in other forms of advanced kidney cancer. This study asked whether that approach could help people whose tumors are specifically FH-deficient, a group often left out of large trials.

The trial (NCT05877820) was an investigator-initiated, open-label, single-arm phase 2 study at Renji Hospital, Shanghai Jiao Tong University School of Medicine. Twenty adults with previously untreated, unresectable advanced or metastatic FH-RCC received lenvatinib 20 mg by mouth once a day plus tislelizumab 200 mg by vein every three weeks. Enrollment ran from September 2023 to December 2024. At the December 22, 2025, data cutoff, median follow-up was 20.2 months (median age 41.5 years; 16 men and 4 women). The main measure was the objective response rate: how many patients’ tumors shrank enough to meet standard imaging criteria for a complete or partial response.

What they found

By the investigators’ assessment, 19 of 20 patients had an objective response (95%), including 4 complete responses and 15 partial responses. Because the trial was small, the paper’s 95% confidence interval for that rate is wide: 75.1% to 99.9%. One patient had stable disease. The disease-control rate was 100%. Every patient had some measurable tumor shrinkage, and no one had primary progression (the cancer growing as its first response to treatment). The median time to response was 6 weeks. Median duration of response was 19.2 months, and median progression-free survival was 20.7 months. Median overall survival had not been reached; the estimated 2-year overall survival rate was 89.7%.

Side effects were common and need to be taken seriously. Every patient had a treatment-related adverse event. Grade 3 events (the more significant ones) occurred in 9 of 20 patients (45%). No grade 4 or higher treatment-related events were reported. The most common side effects of any grade included high blood pressure (80%), thyroid changes (80%), and protein in the urine (70%). The most common grade 3 events were high blood pressure (30%) and joint pain (15%). Lenvatinib was paused or reduced in 13 patients (65%) to help manage side effects. The team also tracked two blood metabolites linked to FH-deficient tumors and reported that these markers followed tumor burden on scans in 80% of patients. They describe that work as exploratory, not something that should change how response is monitored in clinic today.

What this does and does not mean

This is one of the few prospective trials done only in advanced FH-deficient kidney cancer, and a 95% response rate in that setting is encouraging. We are grateful to the patients who took part and to the teams who ran the study. The authors themselves emphasize the limits:

  • It was a small, single-center, single-arm, open-label study. There was no comparison group, and responses were judged by the study investigators without blinded independent central review, so this paper alone cannot show how the combination stacks up against other options. The authors call for larger, multicenter studies. High response rates in a 20-person trial can look different in a larger, multi-center study.
  • It is not a reason to change treatment on your own. First-line therapy decisions belong with an experienced care team who know your history and which medicines are available where you live.
  • An important existing option is bevacizumab plus erlotinib. That combination showed benefit in an NCI-led trial, and GeneReviews notes that it may be beneficial for kidney tumors in this syndrome. We walked through those results in our post on the NEJM bevacizumab and erlotinib trial. The new paper explores another possible approach; it does not replace a conversation with your doctors.

For people with HLRCC who do not have advanced kidney cancer, regular imaging to catch tumors early remains the cornerstone of care. See our post on yearly kidney MRI screening. If you are interested in research participation, visit our Clinical Trials and NIH Enrollment pages, and talk with your care team. Experienced clinicians are listed on our HLRCC Specialists Map.

Join us

Connect with other families in our Facebook group, Knowledge Saves, and read the free HLRCC Handbook. If you’d like to help more families get answers, please consider a gift at hlrcc.org/donate-now.

Sources

  1. Kong W, Xu Y, Liu G, et al. Tislelizumab plus lenvatinib in advanced fumarate hydratase-deficient renal cell carcinoma: a single-arm, phase 2 trial with metabolic biomarker analysis. Nat Commun. 2026 Sep 7;17(1):10591. doi:10.1038/s41467-026-77615-9. PubMed 42844281 · Free full text, PMC13645792
  2. ClinicalTrials.gov. NCT05877820, A Study to Evaluate Efficacy and Safety of Lenvatinib Combined With Tislelizumab in Patients With FHRCC (Renji Hospital; completed; last update Sep 10, 2026). clinicaltrials.gov/study/NCT05877820
  3. Kamihara J, Schultz KA, Rana HQ. FH Tumor Predisposition Syndrome. In: Adam MP, et al., eds. GeneReviews®. University of Washington, Seattle; 2006, comprehensive update May 8, 2025. https://www.ncbi.nlm.nih.gov/books/NBK1252/
  4. Menko FH, Maher ER, Schmidt LS, et al. Hereditary leiomyomatosis and renal cell cancer (HLRCC): renal cancer risk, surveillance and treatment. Fam Cancer. 2014;13(4):637–644. Free full text

Leave a Reply

Your email address will not be published. Required fields are marked *

This is a staging enviroment